This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Akins, R. E. Search for Related Content PubMed PubMed Citation Articles by Akins, R. E. Pubmed/NCBI databases Medline Plus Health Information Heart Diseases

(Circulation Research. 2002;90:120.)
© 2002 American Heart Association, Inc.

Editorials

Can Tissue Engineering Mend Broken Hearts?

Robert E. Akins

From the Department of Biomedical Research, A.I. duPont Hospital for Children, Wilmington, Del.

Correspondence to Robert E. Akins, PhD, Head of Tissue Engineering and Regenerative Medicine Research, Dept of Biomedical Research, A.I. duPont Hospital for Children, PO Box 269, Wilmington, DE 19899. E-mail rakins@nemours.org

Key Words: heart disease • tissue engineering • congenital heart defects • cell biology • surgery

Cardiac tissue engineering is an emerging field that may hold great promise for advancing the treatment of heart diseases. Cardiac tissue engineering is in its infancy, and the overall field of tissue engineering, which was formalized in the late 1980s at conferences and workshops sponsored by the National Science Foundation, is still new enough to warrant some description. By broad definition, tissue engineering involves the construction of tissue equivalents through the manipulation and combination of living cells and biomaterials. It is a multidisciplinary field combining diverse aspects of the life sciences, engineering, and clinical medicine. The overall goal of tissue engineering is to develop tissue equivalents for use in the repair, replacement, maintenance, or augmentation of tissues or organs. Although some aspects of cardiac tissue engineering research have been ongoing for generations, albeit without being known as such, directed efforts in the field are only beginning.

The main justification for cardiac tissue engineering initiatives is straightforward: congenital and acquired heart diseases are substantial health problems, and there is a limited amount of donor tissue for use in surgical repairs. Heart defects are the most common congenital defect and are the leading cause of death in the first year of life.^1,2 Congenital heart defects may occur in as many as 14 of every 1000 live births,³ and approximately 25 000 surgical procedures are performed each year to correct them. Acquired heart diseases also have a profound effect on the population, and despite tremendous advances in medical and surgical treatments, it is . . . [Full Text of this Article]

This article has been cited by other articles:

				S. Salmons Cardiac assistance from skeletal muscle: a reappraisal Eur. J. Cardiothorac. Surg., February 1, 2009; 35(2): 204 - 213. [Abstract] [Full Text] [PDF]

				L. Yin, H. Bien, and E. Entcheva Scaffold topography alters intracellular calcium dynamics in cultured cardiomyocyte networks Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1276 - H1285. [Abstract] [Full Text] [PDF]